DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shih, P.-S.
Right arrow Articles by Huang, J.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shih, P.-S.
Right arrow Articles by Huang, J.-D.

Vol. 30, Issue 12, 1491-1496, December 2002

Pharmacokinetics of Midazolam and 1'-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes

Pei-Shan Shih and Jin-Ding Huang

Department of Pharmacology, College of Medicine, National Cheng Kung University, Taiwan, Republic of China

The CYP3A subfamily represents the most abundant cytochrome P450 in the human liver and gastrointestinal tract and plays very important role in xenobiotic metabolism. CYP3A5 is expressed in a relatively small population of whites and Orientals. We recruited 42 Chinese volunteers to determine the genotypes of CYP3A5 by polymerase chain reaction-restriction fragment length polymorphism. Genotype analyses revealed that CYP3A5*3 allele existed in 39 of 42 volunteers. CYP3A5*4 and CYP3A5*5 alleles were found in one volunteer each; and CYP3A5*2 and CYP3A5*6 alleles were not found. The most frequent CYP3A5*3 allele is known not to express CYP3A5. We excluded other genotypes of CYP3A5 to study the significance of CYP3A5*3 in midazolam pharmacokinetics. In this study, each volunteer was given a midazolam tablet (7.5 mg) orally. Blood samples were collected to analyze the time-dependent concentrations of midazolam and 1'-hydroxymidazolam by high-performance liquid chromatography. The average area under plasma concentration curve (AUC, 0-8 h) of midazolam was 9237 ± 1050 ng-min/ml (mean ± S.E.M.) in homozygous CYP3A5*3 (n = 14) subjects and 7934 ± 768 ng-min/ml in heterozygous CYP3A5*1/*3 (n = 12) subjects, respectively. The average AUC (0-8 h) of 1'-hydroxymidazolam was 3748 ± 427 ng-min/ml in homozygous CYP3A5*3 subjects and 3920 ± 402 ng-min/ml in heterozygous CYP3A5*1/*3 subjects. The results indicated that the pharmacokinetics of midazolam and 1'-hydroxymidazolam was independent of CYP3A5 expression. Although the genetic polymorphism of CYP3A5 is well known, the results of this study suggested that the clinical consequence might be insignificant.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
J. Weiss, M. M. ten Hoevel, J. Burhenne, I. Walter-Sack, M. M. Hoffmann, J. Rengelshausen, W. E. Haefeli, and G. Mikus
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
J. Clin. Pharmacol., February 1, 2009; 49(2): 196 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S.-J. Lee, S. S. Lee, H.-E. Jeong, J.-H. Shon, J.-Y. Ryu, Y. E. Sunwoo, K.-H. Liu, W. Kang, Y.-J. Park, C.-M. Shin, et al.
The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals
Drug Metab. Dispos., November 1, 2007; 35(11): 2095 - 2101.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
Y. M. Kim, S. H. Yoo, R. Y. Kang, M. J. Kim, Y. Y. Bae, Y. K. Lee, S. J. Jeon, K. J. Chon, S. M. Shin, S. G. Kim, et al.
Identifying drugs needing pharmacogenetic monitoring in a Korean hospital
Am. J. Health Syst. Pharm., January 15, 2007; 64(2): 166 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Chen, X.-X. Yang, M. Huang, Z.-P. Hu, M. He, W. Duan, E. Chan, F.-S. Sheu, X. Chen, and S.-F. Zhou
Small Interfering RNA-Mediated Silencing of Cytochrome P450 3A4 Gene
Drug Metab. Dispos., September 1, 2006; 34(9): 1650 - 1657.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. J. Gardiner and E. J. Begg
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. B. Dennison, P. Kulanthaivel, R. J. Barbuch, J. L. Renbarger, W. J. Ehlhardt, and S. D. Hall
SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5
Drug Metab. Dispos., August 1, 2006; 34(8): 1317 - 1327.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. He, M. H. Court, D. J. Greenblatt, and L. L. von Moltke
FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES
Drug Metab. Dispos., July 1, 2006; 34(7): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J.-W. Suh, B.-K. Koo, S.-Y. Zhang, K.-W. Park, J.-Y. Cho, I.-J. Jang, D.-S. Lee, D.-W. Sohn, M.-M. Lee, and H.-S. Kim
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Can. Med. Assoc. J., June 6, 2006; 174(12): 1715 - 1722.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S.-J. Lee, W. J. Jusko, C. G. Salaita, K. A. Calis, M. W. Jann, V. E. Spratlin, J. A. Goldstein, and Y. Y. Hon
Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated With CYP3A5*3 Allele or a Change in Diet Composition.
J. Clin. Pharmacol., May 1, 2006; 46(5): 515 - 526.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. D. Ma, A. N. Nafziger, S. A. Villano, A. Gaedigk, and J. S. Bertino Jr.
Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults.
Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1130 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Henningsson, S. Marsh, W. J. Loos, M. O. Karlsson, A. Garsa, K. Mross, S. Mielke, L. Vigano, A. Locatelli, J. Verweij, et al.
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel
Clin. Cancer Res., November 15, 2005; 11(22): 8097 - 8104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Lepper, S. D. Baker, M. Permenter, N. Ries, R. H.N. van Schaik, P. W. Schenk, D. K. Price, D. Ahn, N. F. Smith, G. Cusatis, et al.
Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients
Clin. Cancer Res., October 15, 2005; 11(20): 7398 - 7404.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
F. Busi and T. Cresteil
CYP3A5 mRNA Degradation by Nonsense-Mediated mRNA Decay
Mol. Pharmacol., September 1, 2005; 68(3): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. D. Baker, R. H. N. van Schaik, L. P. Rivory, A. J. ten Tije, K. Dinh, W. J. Graveland, P. W. Schenk, K. A. Charles, S. J. Clarke, M. A. Carducci, et al.
Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients
Clin. Cancer Res., December 15, 2004; 10(24): 8341 - 8350.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Galetin, C. Brown, D. Hallifax, K. Ito, and J. B. Houston
UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES
Drug Metab. Dispos., December 1, 2004; 32(12): 1411 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Huang, Y. S. Lin, D. J. McConn II, J. C. Calamia, R. A. Totah, N. Isoherranen, M. Glodowski, and K. E. Thummel
EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM
Drug Metab. Dispos., December 1, 2004; 32(12): 1434 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K. Kim, J. A. Johnson, and H. Derendorf
Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms
J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Burk, I. Koch, J. Raucy, E. Hustert, M. Eichelbaum, J. Brockmoller, U. M. Zanger, and L. Wojnowski
The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)
J. Biol. Chem., September 10, 2004; 279(37): 38379 - 38385.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. D. Ma, A. N. Nafziger, and J. S. Bertino Jr.
Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers
J. Clin. Pharmacol., May 1, 2004; 44(5): 447 - 456.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
J. A. Williams, J. Cook, and S. I. Hurst
A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?
Drug Metab. Dispos., December 1, 2003; 31(12): 1526 - 1530.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Westlind-Johnsson, S. Malmebo, A. Johansson, C. Otter, T. B. Andersson, I. Johansson, R. J. Edwards, A. R. Boobis, and M. Ingelman-Sundberg
COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM
Drug Metab. Dispos., June 1, 2003; 31(6): 755 - 761.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.